Trial in Progress: A Randomized, Open-Label, Phase 3 Study of Axatilimab Versus Best Available Therapy in Patients with Chronic Graft-Versus-Host Disease After ≥2 Prior Lines of Systemic Therapy ...

Abstract #S230.) Trial in Progress: A Randomized, Open-Label, Phase 3 Study of Axatilimab Versus Best Available Therapy in Patients with Chronic Graft-Versus-Host Disease After ≥2 Prior Lines of ...

Investing.com -- Shares of Incyte (NASDAQ: INCY) climbed 7% today after the biopharmaceutical company announced that multiple ...

Poster presentations will cover a range of topics, such as the Phase 3 study of Axatilimab for chronic graft-versus-host disease and the efficacy of the BET protein inhibitor INCB057643 in myeloid ...

The company also highlighted data on tafasitamab in combination with lenalidomide and rituximab for relapsed or refractory follicular lymphoma, and various studies on axatilimab for chronic graft ...

Incyte Corporation (NASDAQ:INCY) saw its stock surge 7% after the company announced that multiple research presentations, ...

The company also highlighted data on tafasitamab in combination with lenalidomide and rituximab for relapsed or refractory follicular lymphoma, and various studies on axatilimab for chronic ...

Revumenib abstracts highlight compelling results in acute leukemia across the frontline and R/R setting and multiple genetic populations, including mNPM1, KMT2Ar, and NUP98r – – Axatilimab ...